Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 522

1.

Can therapeutic strategies prevent and manage dyskinesia in Parkinson's disease? An update.

Leta V, Jenner P, Chaudhuri KR, Antonini A.

Expert Opin Drug Saf. 2019 Oct 16. doi: 10.1080/14740338.2019.1681966. [Epub ahead of print]

PMID:
31619083
2.

Reply: Dynamic functional connectivity changes in Lewy body disease.

Biundo R, Fiorenzato E, Antonini A.

Brain. 2019 Oct 12. pii: awz316. doi: 10.1093/brain/awz316. [Epub ahead of print] No abstract available.

PMID:
31605474
3.

Editorial: Impulse Control Disorders, Impulsivity and Related Behaviors in Parkinson's Disease.

Rodríguez-Violante M, Antonini A.

Front Neurol. 2019 Sep 11;10:972. doi: 10.3389/fneur.2019.00972. eCollection 2019. No abstract available.

4.

Stridor in multiple system atrophy: Consensus statement on diagnosis, prognosis, and treatment.

Cortelli P, Calandra-Buonaura G, Benarroch EE, Giannini G, Iranzo A, Low PA, Martinelli P, Provini F, Quinn N, Tolosa E, Wenning GK, Abbruzzese G, Bower P, Alfonsi E, Ghorayeb I, Ozawa T, Pacchetti C, Pozzi NG, Vicini C, Antonini A, Bhatia KP, Bonavita J, Kaufmann H, Pellecchia MT, Pizzorni N, Schindler A, Tison F, Vignatelli L, Meissner WG.

Neurology. 2019 Oct 1;93(14):630-639. doi: 10.1212/WNL.0000000000008208. Review.

PMID:
31570638
5.

Non-motor outcomes depend on location of neurostimulation in Parkinson's disease.

Petry-Schmelzer JN, Krause M, Dembek TA, Horn A, Evans J, Ashkan K, Rizos A, Silverdale M, Schumacher W, Sack C, Loehrer PA, Fink GR, Fonoff ET, Martinez-Martin P, Antonini A, Barbe MT, Visser-Vandewalle V, Ray-Chaudhuri K, Timmermann L, Dafsari HS.

Brain. 2019 Sep 23. pii: awz285. doi: 10.1093/brain/awz285. [Epub ahead of print]

PMID:
31553039
6.

Deep brain stimulation in Parkinson's disease: A multicentric, long-term, observational pilot study.

Scelzo E, Beghi E, Rosa M, Angrisano S, Antonini A, Bagella C, Bianchi E, Caputo E, Lena F, Lopiano L, Marcante A, Marceglia S, Massaro F, Modugno N, Pacchetti C, Pilleri M, Pozzi NG, Romito LM, Santilli M, Tamma F, Weis L, Zibetti M, Priori A.

J Neurol Sci. 2019 Aug 21;405:116411. doi: 10.1016/j.jns.2019.07.029. [Epub ahead of print]

PMID:
31476620
7.

Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease.

Fiorenzato E, Antonini A, Camparini V, Weis L, Semenza C, Biundo R.

J Neural Transm (Vienna). 2019 Aug 20. doi: 10.1007/s00702-019-02065-1. [Epub ahead of print]

PMID:
31432258
8.

Wolf Rock lighthouse: past developments and future survivability under wave loading.

Raby AC, Antonini A, Pappas A, Dassanayake DT, Brownjohn JMW, D'Ayala D.

Philos Trans A Math Phys Eng Sci. 2019 Sep 7;377(2155):20190027. doi: 10.1098/rsta.2019.0027. Epub 2019 Aug 19.

9.

Environmental loading of heritage structures.

Raby A, Antonini A, D'Ayala D, Brownjohn JMW.

Philos Trans A Math Phys Eng Sci. 2019 Sep 7;377(2155):20190276. doi: 10.1098/rsta.2019.0276. Epub 2019 Aug 19. No abstract available.

10.

Frontal and subcortical contribution to visual hallucinations in dementia with Lewy bodies and Parkinson's disease.

Pezzoli S, Cagnin A, Antonini A, Venneri A.

Postgrad Med. 2019 Sep;131(7):509-522. doi: 10.1080/00325481.2019.1656515. Epub 2019 Aug 28.

PMID:
31422718
11.

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.

Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A.

J Parkinsons Dis. 2019;9(3):531-541. doi: 10.3233/JPD-191605.

12.

Dynamic functional connectivity changes associated with dementia in Parkinson's disease.

Fiorenzato E, Strafella AP, Kim J, Schifano R, Weis L, Antonini A, Biundo R.

Brain. 2019 Sep 1;142(9):2860-2872. doi: 10.1093/brain/awz192.

PMID:
31280293
13.

The PRIAMO study: active sexual life is associated with better motor and non-motor outcomes in men with early Parkinson's disease.

Picillo M, Palladino R, Erro R, Colosimo C, Marconi R, Antonini A, Barone P; PRIAMO study group.

Eur J Neurol. 2019 Oct;26(10):1327-1333. doi: 10.1111/ene.13983. Epub 2019 Jul 2.

14.

Feasibility of a multidisciplinary approach for medical review among elderly patients in four Italian long-term nursing homes.

Cattaruzzi C, Cadelli L, Marcuzzo L, Antonini A, Groppo B, Ros B, Tosolini M, Lemessi N.

Eur J Hosp Pharm. 2018 Jul;25(4):207-209. doi: 10.1136/ejhpharm-2015-000812. Epub 2016 May 24.

15.

Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.

Lopiano L, Modugno N, Marano P, Sensi M, Meco G, Solla P, Gusmaroli G, Tamma F, Mancini F, Quatrale R, Zangaglia R, Bentivoglio A, Eleopra R, Gualberti G, Melzi G, Antonini A.

J Neurol. 2019 Sep;266(9):2164-2176. doi: 10.1007/s00415-019-09337-6. Epub 2019 May 27.

16.

Long-term effect of subthalamic and pallidal deep brain stimulation for status dystonicus in children with methylmalonic acidemia and GNAO1 mutation.

Benato A, Carecchio M, Burlina A, Paoloni F, Sartori S, Nosadini M, d'Avella D, Landi A, Antonini A.

J Neural Transm (Vienna). 2019 Jun;126(6):739-757. doi: 10.1007/s00702-019-02010-2. Epub 2019 May 10.

PMID:
31076915
17.

A critique of the second consensus criteria for multiple system atrophy.

Stankovic I, Quinn N, Vignatelli L, Antonini A, Berg D, Coon E, Cortelli P, Fanciulli A, Ferreira JJ, Freeman R, Halliday G, Höglinger GU, Iodice V, Kaufmann H, Klockgether T, Kostic V, Krismer F, Lang A, Levin J, Low P, Mathias C, Meissner WG, Kaufmann LN, Palma JA, Panicker JN, Pellecchia MT, Sakakibara R, Schmahmann J, Scholz SW, Singer W, Stamelou M, Tolosa E, Tsuji S, Seppi K, Poewe W, Wenning GK; Movement Disorder Society Multiple System Atrophy Study Group.

Mov Disord. 2019 Jul;34(7):975-984. doi: 10.1002/mds.27701. Epub 2019 Apr 29. No abstract available.

PMID:
31034671
18.

Dermoscopic similarity is an independent predictor of BRAF mutational concordance in multiple melanomas.

Moscarella E, Pellegrini C, Pampena R, Argenziano G, Manfredini M, Martorelli C, Ciarrocchi A, Dika E, Peris K, Antonini A, Cipolloni G, Alfano R, Longo C, Fargnoli MC.

Exp Dermatol. 2019 Jul;28(7):829-835. doi: 10.1111/exd.13951. Epub 2019 May 10.

PMID:
31034104
19.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB.

Alzheimers Dement (Amst). 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

20.

Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?

Chaudhuri KR, Jenner P, Antonini A.

Mov Disord. 2019 Jun;34(6):816-819. doi: 10.1002/mds.27691. Epub 2019 Apr 14. No abstract available.

PMID:
30983023
21.

Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease.

Martini A, Weis L, Fiorenzato E, Schifano R, Cianci V, Antonini A, Biundo R.

Front Neurol. 2019 Mar 22;10:266. doi: 10.3389/fneur.2019.00266. eCollection 2019.

22.

Dysphagia predicts poor outcome in late-stage Parkinson's disease.

Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, Cardoso R, Guimaraes I, Antonini A, Zibetti M, Lopiano L, Ferreira JJ.

Parkinsonism Relat Disord. 2019 Jul;64:73-81. doi: 10.1016/j.parkreldis.2019.02.043. Epub 2019 Mar 2.

PMID:
30902528
23.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Aug;34(8):1228-1232. doi: 10.1002/mds.27666. Epub 2019 Mar 18.

24.

Relationship of Nocturnal Sleep Dysfunction and Pain Subtypes in Parkinson's Disease.

Martinez-Martin P, Rizos AM, Wetmore JB, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR; EUROPAR & MDS Non‐Motor PD Study Group.

Mov Disord Clin Pract. 2018 Nov 8;6(1):57-64. doi: 10.1002/mdc3.12694. eCollection 2019 Jan.

PMID:
30746417
25.

EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.

Dafsari HS, Martinez-Martin P, Rizos A, Trost M, Dos Santos Ghilardi MG, Reddy P, Sauerbier A, Petry-Schmelzer JN, Kramberger M, Borgemeester RWK, Barbe MT, Ashkan K, Silverdale M, Evans J, Odin P, Fonoff ET, Fink GR, Henriksen T, Ebersbach G, Pirtošek Z, Visser-Vandewalle V, Antonini A, Timmermann L, Ray Chaudhuri K; EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson's Disease Study Group.

Mov Disord. 2019 Mar;34(3):353-365. doi: 10.1002/mds.27626. Epub 2019 Feb 4.

PMID:
30719763
26.

Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Kuusimäki T, Korpela J, Pekkonen E, Martikainen MH, Antonini A, Kaasinen V.

J Neurol. 2019 Jan 18. doi: 10.1007/s00415-019-09181-8. [Epub ahead of print] Review.

PMID:
30659355
27.

Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry.

Poewe W, Chaudhuri KR, Bergmann L, Antonini A.

Neurodegener Dis Manag. 2019 Feb;9(1):39-46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14.

28.

A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium.

Oppedal K, Ferreira D, Cavallin L, Lemstra AW, Ten Kate M, Padovani A, Rektorova I, Bonanni L, Wahlund LO, Engedal K, Nobili F, Kramberger M, Taylor JP, Hort J, Snædal J, Blanc F, Walker Z, Antonini A, Westman E, Aarsland D; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2019 Mar;15(3):400-409. doi: 10.1016/j.jalz.2018.09.011. Epub 2018 Nov 12.

PMID:
30439333
29.

Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel.

Ray Chaudhuri K, Antonini A, Robieson WZ, Sanchez-Soliño O, Bergmann L, Poewe W; GLORIA study co-investigators.

Eur J Neurol. 2019 Apr;26(4):581-e43. doi: 10.1111/ene.13847. Epub 2018 Dec 26.

30.

Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson's Disease: The PPMI Dataset.

Fiorenzato E, Biundo R, Cecchin D, Frigo AC, Kim J, Weis L, Strafella AP, Antonini A.

J Alzheimers Dis. 2018;66(1):229-237. doi: 10.3233/JAD-180390.

PMID:
30282359
31.

Apomorphine infusion in advanced Parkinson disease.

Antonini A, Jenner P.

Nat Rev Neurol. 2018 Dec;14(12):693-694. doi: 10.1038/s41582-018-0083-y. No abstract available.

PMID:
30279608
32.

USP14 inhibition corrects an in vivo model of impaired mitophagy.

Chakraborty J, von Stockum S, Marchesan E, Caicci F, Ferrari V, Rakovic A, Klein C, Antonini A, Bubacco L, Ziviani E.

EMBO Mol Med. 2018 Nov;10(11). pii: e9014. doi: 10.15252/emmm.201809014.

33.

Regulation of ER-mitochondria contacts by Parkin via Mfn2.

Basso V, Marchesan E, Peggion C, Chakraborty J, von Stockum S, Giacomello M, Ottolini D, Debattisti V, Caicci F, Tasca E, Pegoraro V, Angelini C, Antonini A, Bertoli A, Brini M, Ziviani E.

Pharmacol Res. 2018 Dec;138:43-56. doi: 10.1016/j.phrs.2018.09.006. Epub 2018 Sep 13.

34.

Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial.

Antonini A, Gentile G, Giglio M, Marcante A, Gage H, Touray MML, Fotiadis DI, Gatsios D, Konitsiotis S, Timotijevic L, Egan B, Hodgkins C, Biundo R, Pellicano C; PD_Manager consortium.

Trials. 2018 Sep 14;19(1):492. doi: 10.1186/s13063-018-2767-4.

35.

Disease progression in Parkinson subtypes: the PPMI dataset.

Aleksovski D, Miljkovic D, Bravi D, Antonini A.

Neurol Sci. 2018 Nov;39(11):1971-1976. doi: 10.1007/s10072-018-3522-z. Epub 2018 Aug 14.

PMID:
30109466
36.

[Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].

Antonini A, Jost WH.

Fortschr Neurol Psychiatr. 2018 Sep;86(S 01):S5-S9. doi: 10.1055/a-0646-4164. Epub 2018 Aug 14. Review. German.

PMID:
30107620
37.

Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach.

Antonini A, Stoessl AJ, Kleinman LS, Skalicky AM, Marshall TS, Sail KR, Onuk K, Odin PLA.

Curr Med Res Opin. 2018 Dec;34(12):2063-2073. doi: 10.1080/03007995.2018.1502165. Epub 2018 Aug 20.

PMID:
30016901
38.

Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.

Antonini A, Nitu B.

J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135. doi: 10.1007/s00702-018-1906-0. Epub 2018 Jul 13. Review.

PMID:
30006821
39.

First comprehensive tool for screening pain in Parkinson's disease: the King's Parkinson's Disease Pain Questionnaire.

Martinez-Martin P, Rizos AM, Wetmore J, Antonini A, Odin P, Pal S, Sophia R, Carroll C, Martino D, Falup-Pecurariu C, Kessel B, Andrews T, Paviour D, Trenkwalder C, Chaudhuri KR; EUROPAR and MDS Non-motor PD Study Group.

Eur J Neurol. 2018 Oct;25(10):1255-1261. doi: 10.1111/ene.13691. Epub 2018 Jun 22.

PMID:
29806962
40.

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.

Odin P, Chaudhuri KR, Volkmann J, Antonini A, Storch A, Dietrichs E, Pirtošek Z, Henriksen T, Horne M, Devos D, Bergquist F.

NPJ Parkinsons Dis. 2018 May 10;4:14. doi: 10.1038/s41531-018-0051-7. eCollection 2018. Review.

41.

Interferon-beta injection site reactions in patients with multiple sclerosis.

Maurelli M, Bergamaschi R, Antonini A, Fargnoli MC, Puma E, Mallucci G, Totaro R, Girolomoni G.

J Dermatolog Treat. 2018 Dec;29(8):831-834. doi: 10.1080/09546634.2018.1467539. Epub 2018 May 7. Review.

PMID:
29671656
42.

Short-term quality of life after subthalamic stimulation depends on non-motor symptoms in Parkinson's disease.

Dafsari HS, Weiß L, Silverdale M, Rizos A, Reddy P, Ashkan K, Evans J, Reker P, Petry-Schmelzer JN, Samuel M, Visser-Vandewalle V, Antonini A, Martinez-Martin P, Ray-Chaudhuri K, Timmermann L; EUROPAR and the IPMDS Non Motor PD Study Group.

Brain Stimul. 2018 Jul - Aug;11(4):867-874. doi: 10.1016/j.brs.2018.02.015. Epub 2018 Feb 24.

PMID:
29655587
43.

Non-motor outcomes of subthalamic stimulation in Parkinson's disease depend on location of active contacts.

Dafsari HS, Petry-Schmelzer JN, Ray-Chaudhuri K, Ashkan K, Weis L, Dembek TA, Samuel M, Rizos A, Silverdale M, Barbe MT, Fink GR, Evans J, Martinez-Martin P, Antonini A, Visser-Vandewalle V, Timmermann L; EUROPAR; IPMDS Non Motor PD Study Group.

Brain Stimul. 2018 Jul - Aug;11(4):904-912. doi: 10.1016/j.brs.2018.03.009. Epub 2018 Mar 16.

PMID:
29655586
44.

Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease.

Antonini A, Robieson WZ, Bergmann L, Yegin A, Poewe W.

Neurodegener Dis Manag. 2018 Jun;8(3):161-170. doi: 10.2217/nmt-2017-0046. Epub 2018 Apr 10.

45.

Multifocal alterations of white matter accompany the transition from normal cognition to dementia in Parkinson's disease patients.

Chondrogiorgi M, Astrakas LG, Zikou AK, Weis L, Xydis VG, Antonini A, Argyropoulou MI, Konitsiotis S.

Brain Imaging Behav. 2019 Feb;13(1):232-240. doi: 10.1007/s11682-018-9863-7.

PMID:
29629498
46.

A new dermoscopic algorithm for the differential diagnosis of facial lentigo maligna and pigmented actinic keratosis.

Micantonio T, Neri L, Longo C, Grassi S, Di Stefani A, Antonini A, Coco V, Fargnoli MC, Argenziano G, Peris K.

Eur J Dermatol. 2018 Apr 1;28(2):162-168. doi: 10.1684/ejd.2018.3246.

PMID:
29620004
47.

Medical and surgical management of advanced Parkinson's disease.

Antonini A, Moro E, Godeiro C, Reichmann H.

Mov Disord. 2018 Jul;33(6):900-908. doi: 10.1002/mds.27340. Epub 2018 Mar 23. Review.

PMID:
29570862
48.

Pain in Parkinson's disease: facts and uncertainties.

Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O.

Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18. Review.

PMID:
29520899
49.

Caregiver burden and its related factors in advanced Parkinson's disease: data from the PREDICT study.

Tessitore A, Marano P, Modugno N, Pontieri FE, Tambasco N, Canesi M, Latorre A, Lopiano L, Sensi M, Quatrale R, Solla P, Defazio G, Melzi G, Costanzo AM, Gualberti G, di Luzio Paparatti U, Antonini A.

J Neurol. 2018 May;265(5):1124-1137. doi: 10.1007/s00415-018-8816-9. Epub 2018 Mar 7.

50.

Nonmotor symptoms evolution during 24 months of bilateral subthalamic stimulation in Parkinson's disease.

Dafsari HS, Silverdale M, Strack M, Rizos A, Ashkan K, Mahlstedt P, Sachse L, Steffen J, Dembek TA, Visser-Vandewalle V, Evans J, Antonini A, Martinez-Martin P, Ray-Chaudhuri K, Timmermann L; EUROPAR and the IPMDS Non Motor PD Study Group.

Mov Disord. 2018 Mar;33(3):421-430. doi: 10.1002/mds.27283. Epub 2018 Feb 21.

PMID:
29465787

Supplemental Content

Loading ...
Support Center